Clinical significance of Janus Kinase inhibitor selectivity
用户qgRSP4os3S6M
10天前
31
10
已完结
1. 系统已在2025-10-01 14:32:56对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
EH Choy
Rheumatology, 2019
academic.oup.com
… Non-melanoma skin cancer occurred in 0.6/100 patient years (95% CI 0.5–0.7) for tofacitinib … mAbs, are more likely to have off-target side effects that may not be associated with JAK …
